Isit Tuximab After Darrertumumab?

I think once Isit Tuximab gets a subcutaneous version, it's going to become very competitive with Darrertumumab. So the right patient is it, they should not be Darrertums refractory because it's the same CD38 monochrome landy body. Six months would be the least amount of time I would use. The other place where I don't mind using Isit if I'm combining it with carfilzumab,. so I am going to be giving something intravenously. I do not mind giving IV Isit, otherwise it becomes hard to justify the use of an intravenous monochromeLandy body when you